Soininen H, Pitkänen A, Halonen T, Riekkinen P J
Acta Neurol Scand. 1984 Jul;70(1):29-34. doi: 10.1111/j.1600-0404.1984.tb00799.x.
Recent neurochemical studies have indicated that in Alzheimer's disease there is disturbance of the cholinergic metabolism of the brain. Defects in other transmitter systems have also been suggested. As a marker of noradrenergic metabolism of the central nervous system, we measured dopamine-beta-hydroxylase (EC. 1.14.17.1) activity in cerebrospinal fluid (CSF) from 60 Alzheimer patients and 20 controls of the same age and sex. Dopamine-beta-hydroxylase activities of the CSF from Alzheimer patients did not differ significantly from those for the controls. The dopamine-beta-hydroxylase activities were not correlated with severity of dementia. As reported previously, the activity of a cholinergic marker, acetylcholinesterase (EC 3.1.1.7), was reduced in the CSF of Alzheimer patients. Interestingly, dopamine-beta-hydroxylase activities were correlated with acetylcholinesterase activities both in Alzheimer patients and control group.
近期的神经化学研究表明,在阿尔茨海默病中,大脑的胆碱能代谢存在紊乱。也有人提出其他递质系统存在缺陷。作为中枢神经系统去甲肾上腺素能代谢的标志物,我们检测了60例阿尔茨海默病患者及20例年龄和性别匹配的对照者脑脊液(CSF)中的多巴胺-β-羟化酶(EC. 1.14.17.1)活性。阿尔茨海默病患者脑脊液中的多巴胺-β-羟化酶活性与对照组相比无显著差异。多巴胺-β-羟化酶活性与痴呆严重程度无关。如先前报道,阿尔茨海默病患者脑脊液中胆碱能标志物乙酰胆碱酯酶(EC 3.1.1.7)的活性降低。有趣的是,阿尔茨海默病患者组和对照组中,多巴胺-β-羟化酶活性均与乙酰胆碱酯酶活性相关。